| Q28078766 | "Freeze, Don't Move": How to Arrest a Suspect in Heart Failure - A Review on Available GRK2 Inhibitors |
| Q42609302 | 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials |
| Q50761995 | 30-year follow-up of a patient with classic citrullinemia. |
| Q33999694 | A comparison of sympathoadrenal activity and cardiac performance at rest and during exercise in patients with ventricular demand or atrial synchronous pacing |
| Q37538767 | A modified approach to induce predictable congestive heart failure by volume overload in rats |
| Q34872068 | A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure |
| Q61608683 | A temporal window of vulnerability for development of atrial fibrillation with advancing heart failure |
| Q37576148 | A translational approach to probe the proarrhythmic potential of cardiac alternans: a reversible overture to arrhythmogenesis? |
| Q35879498 | A-kinase anchoring protein targeting of protein kinase A in the heart |
| Q47551370 | AAV-9 mediated phosphatase-1 inhibitor-1 overexpression improves cardiac contractility in unchallenged mice but is deleterious in pressure-overload |
| Q36992792 | AKAP150 participates in calcineurin/NFAT activation during the down-regulation of voltage-gated K(+) currents in ventricular myocytes following myocardial infarction. |
| Q33577431 | Abnormal haemodynamic postural response in patients with chronic heart failure |
| Q52017734 | Abnormal left ventricular ejection fraction response to mental stress and exercise in cardiomyopathy. |
| Q35660566 | Absence of SOCS3 in the cardiomyocyte increases mortality in a gp130-dependent manner accompanied by contractile dysfunction and ventricular arrhythmias |
| Q70188878 | Accelerated systemic hypertension after cardiac transplantation—possible vascular alpha-receptor hypersensitivity |
| Q73156963 | Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease |
| Q41442471 | Activation of the neuroendocrine response in heart failure: adaptive or maladaptive process? |
| Q68297731 | Acute and chronic hemodynamic effects of xamoterol in mild to moderate congestive heart failure |
| Q73614668 | Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction |
| Q48298572 | Acute brain death alters left ventricular myocardial gene expression |
| Q35189178 | Acute circulatory support |
| Q54268897 | Acute effects of intravenous phosphodiesterase inhibition in chronic heart failure: simultaneous pre- and afterload reduction with a single agent |
| Q54363557 | Acute haemodynamic effects of different doses of alifedrine in congestive heart failure. |
| Q43448997 | Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure |
| Q69624378 | Additive positive inotropic effects of milrinone, ouabain and calcium in diseased human ventricular myocardium |
| Q64380499 | Adenovirus-mediated genetic manipulation of the myocardial beta-adrenergic signaling system in transplanted hearts |
| Q37704624 | Adenylyl cyclase 6 deletion increases mortality during sustained β-adrenergic receptor stimulation |
| Q37054928 | Adenylyl cyclase type 5 in cardiac disease, metabolism, and aging. |
| Q37776088 | Adrenergic Signaling Polymorphisms and Their Impact on Cardiovascular Disease |
| Q37467503 | Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. |
| Q37349756 | Adrenergic nervous system in heart failure: pathophysiology and therapy |
| Q38195518 | Adrenergic signaling in heart failure: a balance of toxic and protective effects |
| Q35002036 | Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy. |
| Q70309574 | Alcohol and the heart |
| Q37692816 | Alpha-1-adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulation |
| Q34892203 | Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure |
| Q40379297 | Alterations of beta-adrenoceptor-G-protein-regulated adenylyl cyclase in heart failure |
| Q42521714 | Alterations of cardiac beta-adrenoceptor mechanisms due to calcium depletion and repletion |
| Q43150579 | Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity. |
| Q44835151 | Alterations of the cAMP-adenylate cyclase system in the failing human heart. Consequences for the therapy with inotropic drugs |
| Q71866965 | Altered inotropism in the failing human myocardium |
| Q71617069 | Altered responsiveness to endothelin-1 of myocardium from pacing-induced heart failure model in the dog |
| Q41788382 | Alternative signaling: cardiomyocyte beta1-adrenergic receptors signal through EGFRs |
| Q74341686 | An animal model of arrhythmogenesis in congestive heart failure |
| Q34242144 | An evaluation of the safety of the beta-modulator cicloprolol in chronic heart failure |
| Q36499620 | An overview of beta-adrenoceptors and signal transduction — desensitization in cardiac disease and effect of beta-blockade |
| Q51605284 | Anaesthetic induction in a child with end-stage cardiomyopathy. |
| Q54741885 | Analysis of GNAS1 and PRKAR1A gene mutations in human cardiac myxomas not associated with multiple endocrine disorders. |
| Q35329086 | Angiotensin converting enzyme inhibitors versus digoxin for the treatment of congestive heart failure |
| Q74152283 | Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure |
| Q44959302 | Antioxidant and oxidative stress changes in experimental cor pulmonale |
| Q46261246 | Application of kinetic resolution using HCS as chiral auxiliary: novel synthesis of beta-blockers (S)-betaxolol and (S)-metoprolol |
| Q58121711 | Arrhythmogenic Mechanisms in Heart Failure: Linking β-Adrenergic Stimulation, Stretch, and Calcium |
| Q45025727 | Aspartate138 is required for the high-affinity ligand binding site but not for the low-affinity binding site of the beta1-adrenoceptor |
| Q58614496 | Assessment of PKA and PKC inhibitors on force and kinetics of non-failing and failing human myocardium |
| Q54462835 | Assessment of calcium homeostasis in the critically ill surgical patient. The diagnostic pitfalls of the McLean-Hastings nomogram. |
| Q92740551 | Association of patient-reported outcomes and heart rate trends in heart failure: a report from the Chiron project |
| Q33974952 | Attenuated fatigue in slow twitch skeletal muscle during isotonic exercise in rats with chronic heart failure |
| Q35980401 | Augmenting beta receptors in the heart: short-term gains offset by long-term pains? |
| Q92526572 | Autonomic Dysfunction Increases Cardiovascular Risk in the Presence of Sleep Apnea |
| Q34249819 | Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations |
| Q39267607 | Barcoding of GPCR trafficking and signaling through the various trafficking roadmaps by compartmentalized signaling networks |
| Q41943947 | Baroreflex and beta-adrenoceptor function are diminished in rat cardiac hypertrophy due to volume overload |
| Q77141936 | Basic mechanisms of disease progression in the failing heart: the role of excessive adrenergic drive |
| Q77945695 | Bbeta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by beta- but not alpha1-adrenergic stimulation |
| Q36820546 | Beta adrenoceptor density in the donor heart: a guide to prognosis? |
| Q28379279 | Beta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses |
| Q24792845 | Beta-Adrenergic gene therapy for cardiovascular disease |
| Q37423781 | Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy. |
| Q41737497 | Beta-adrenergic blockade in chronic heart failure. |
| Q73292093 | Beta-adrenergic blockers in the treatment of pediatric heart failure |
| Q39466013 | Beta-adrenergic blockers. |
| Q38338608 | Beta-adrenergic blocking drugs in the treatment of congestive heart failure. |
| Q42494338 | Beta-adrenergic blood pressure regulation in Shy-Drager syndrome and pheochromocytoma |
| Q35598979 | Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms |
| Q30321379 | Beta-adrenergic receptors in failing human myocardium. |
| Q40305882 | Beta-adrenergic receptors in heart failure |
| Q42690740 | Beta-adrenergic receptors signaling and heart failure in mice, rabbits and humans |
| Q46234079 | Beta-adrenergic signaling in heart failure-adapt or die. |
| Q37358922 | Beta-adrenergic stimulation and myocardial function in the failing heart |
| Q36704776 | Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure |
| Q44324315 | Beta-adrenoceptor density on mononuclear leukocytes and right atrial myocardium in infants and children with congenital heart disease |
| Q42521118 | Beta-adrenoceptor mediated signal transduction in congestive heart failure in cardiomyopathic (UM-X7.1) hamsters. |
| Q52178974 | Beta2-adrenergic receptor overexpression in the developing mouse heart: evidence for targeted modulation of ion channels. |
| Q36342091 | Biased β2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery |
| Q44827536 | Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers |
| Q67486772 | Binding of Beta-Adrenergic Receptors in Human Skin |
| Q40092691 | Biochemical, structural and mechanical defects of the failing myocardium |
| Q34048279 | Blunted cardiac beta-adrenergic response as an early indication of cardiac dysfunction in Duchenne muscular dystrophy |
| Q43749548 | Both cell surface and internalized β-adrenoceptors are reduced in the failing myocardium |
| Q91890405 | CXCR4 Cardiac Specific Knockout Mice Develop a Progressive Cardiomyopathy |
| Q67882209 | Can intravenous beta blockade predict long-term haemodynamic benefit in chronic congestive heart failure secondary to ischaemic heart disease? A comparison between intravenous and oral carvedilol |
| Q37428727 | Capturing adenylyl cyclases as potential drug targets |
| Q38542448 | Cardiac Physiology of Aging: Extracellular Considerations. |
| Q38746072 | Cardiac abnormalities in liver cirrhosis |
| Q37432103 | Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance |
| Q35897263 | Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure |
| Q42445481 | Cardiac beta-adrenoceptor desensitization after sinoaortic baroreceptors denervation or isoproterenol-pretreatment. |
| Q72301992 | Cardiac chamber-specific beta-adrenoceptor regulation and sympathetic innervation |
| Q28504814 | Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor |
| Q46287213 | Cardiac inotropic responses to calcium and forskolin are not altered by prolonged isoproterenol infusion |
| Q37962818 | Cardiac myosin binding protein C phosphorylation in cardiac disease. |
| Q37693685 | Cardiac myosin binding protein-C Ser302 phosphorylation regulates cardiac β-adrenergic reserve |
| Q37142782 | Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice |
| Q69890605 | Cardiac pumping capability and prognosis in heart failure |
| Q81606489 | Cardiac receptor physiology and imaging: an update |
| Q40831915 | Cardiac remodeling as a consequence and cause of progressive heart failure. |
| Q34973985 | Cardiac sequelae of hypertension |
| Q28077143 | Cardiac sympathetic activity in chronic heart failure: cardiac 123I-mIBG scintigraphy to improve patient selection for ICD implantation |
| Q48788454 | Cardiac β-adrenergic receptor density and myocardial systolic function in the remote noninfarcted region after prior myocardial infarction with left ventricular remodelling |
| Q70162646 | Cardiac β-adrenoceptor modulation by amiodarone |
| Q34718192 | Cardiomyocyte lipids impair β-adrenergic receptor function via PKC activation |
| Q36006132 | Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase |
| Q70165214 | Cardiopulmonary response to sodium fluoride infusion in the dog |
| Q38068097 | Cardiorenal syndrome: pathophysiology and potential targets for clinical management |
| Q86811462 | Cardiorenal syndrome: review of our current understanding |
| Q53851435 | Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action |
| Q35026897 | Cardiovascular effects of the novel Ca2+-sensitiser EMD 57033 in pigs at rest and during treadmill exercise |
| Q27014770 | Cardiovascular gene therapy for myocardial infarction |
| Q30470859 | Cardiovascular molecular imaging: focus on clinical translation |
| Q41840874 | Carvedilol tratment of chronic heart failure: a new era. |
| Q42346374 | Case 2/2017 - 56-Year-Old Male with Refractory Heart Failure, Systemic Arterial Hypertension and Aortic Valve Stenosis That Led to Heart Transplantation |
| Q42445006 | Catecholamine Responsive Adenylate Cyclase in Human Myocardial Preparations Properties and Optimalization of Assay Conditions |
| Q39702708 | Catecholamines in critical care. |
| Q40542589 | Cellular adaptations of the myocardium to chronic exercise |
| Q34661152 | Central sleep apnoea syndrome in patients with chronic heart disease: a critical review of the current literature |
| Q37977339 | Centrally acting sympatholytic agents in the treatment of congestive heart failure. A review of the literature |
| Q42456202 | Changes in L-type calcium channel abundance and function during the transition to pacing-induced congestive heart failure |
| Q35581669 | Changes in adrenergic receptors during the development of heart failure |
| Q41252619 | Changes in beta-adrenoceptors and G-proteins during the transition from cardiac hypertrophy to heart failure |
| Q36082110 | Changes in cardiac physiology after severe burn injury |
| Q51824146 | Changes in cyclic nucleotide phosphodiesterase activity and calmodulin concentration in heart muscle of cardiomyopathic hamsters. |
| Q36469346 | Changing Strategies in the Management of Chronic Congestive Heart Failure |
| Q35755024 | Characterization and autoradiographic localization of beta-adrenoceptor subtypes in human cardiac tissues |
| Q28363078 | Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium |
| Q67524752 | Characterization of cell-surface beta-adrenergic ([3H]CGP-12177) binding in adult rat ventricular myocytes: lack of regulation by beta-agonists at physiological concentrations |
| Q40395715 | Choosing the right beta-blocker. A guide to selection |
| Q30578491 | Chronic alcohol consumption from adolescence-to-adulthood in mice--hypothalamic gene expression changes in the dilated cardiomyopathy signaling pathway |
| Q34774421 | Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia |
| Q37288542 | Chronic heart failure: beta-blockers and pharmacogenetics |
| Q33620431 | Chronic heart failure: contemporary diagnosis and management |
| Q50092278 | Chronic low-intensity exercise attenuates cardiomyocyte contractile dysfunction and impaired adrenergic responsiveness in aortic-banded mini-swine. |
| Q34214425 | Chronic nonocclusive coronary artery constriction in rats. Beta-adrenoceptor signal transduction and ventricular failure |
| Q40380445 | Chronic norepinephrine elicits desensitization by uncoupling the beta-receptor |
| Q28505358 | Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy |
| Q44268627 | Chronotropic and inotropic responses to adrenoceptor agonists in vitro after chronic dobutamine treatment in the rabbit |
| Q71995869 | Chronotropic incompetence in chronic heart failure |
| Q41099226 | Chronotropic incompetence--Part II: Clinical implications |
| Q54500889 | Clonidine in congestive heart failure: a vasodilator with negative inotropic effects. |
| Q48870938 | Combined intravenous pharmacotherapy in the treatment of patients with decompensated congestive heart failure |
| Q68424322 | Comparative effects of enoximone and theophylline on plasma catecholamines and haemodynamics in cardiosurgical patients |
| Q71343619 | Comparison of calcium-current in isolated atrial myocytes from failing and nonfailing human hearts |
| Q70635845 | Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure |
| Q70217019 | Comparison of rat and human left ventricle beta-adrenergic receptors: Subtype heterogeneity delineated by direct radioligand binding |
| Q35888008 | Comparison of the effects of xamoterol and isoprenaline on rat cardiac beta-adrenoceptors: studies of function and regulation |
| Q41206403 | Conducting the G-protein Coupled Receptor (GPCR) Signaling Symphony in Cardiovascular Diseases: New Therapeutic Approaches |
| Q39672687 | Congestive cardiac failure: central role of the arterial blood pressure |
| Q80577437 | Congestive heart failure in the elderly |
| Q34247208 | Contractile reserve assessed by dobutamine test identifies super-responders to cardiac resynchronization therapy |
| Q38549058 | Contractility and inhibition of protein phosphatases by cantharidin |
| Q37671204 | Convergence of G protein-coupled receptor and S-nitrosylation signaling determines the outcome to cardiac ischemic injury |
| Q46246053 | Correlation between beta-adrenoceptors and G-protein-coupled receptor kinases in pretransplantation heart failure |
| Q72334327 | Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay |
| Q77896707 | Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes |
| Q33816471 | Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients |
| Q36421513 | Critical Roles of STAT3 in β-Adrenergic Functions in the Heart |
| Q39193265 | Cross-Talk Between Insulin Signaling and G Protein-Coupled Receptors |
| Q37232104 | Current and future G protein-coupled receptor signaling targets for heart failure therapy |
| Q30646769 | Cutaneous blood flow and adrenoceptor response increase in segmental-type vitiligo lesions |
| Q97528479 | DMD Pluripotent Stem Cell Derived Cardiac Cells Recapitulate in vitro Human Cardiac Pathophysiology |
| Q74152208 | Dantrolene sodium improves the force-frequency relationship and beta-adregenic responsiveness in failing human myocardium |
| Q36719531 | Deceleration and acceleration capacities of heart rate associated with heart failure with high discriminating performance |
| Q34076156 | Decoding calcium signals involved in cardiac growth and function |
| Q34177840 | Decreased Gs alpha mRNA levels accompany the fall in Gs and adenylyl cyclase activities in compensated left ventricular hypertrophy. In heart failure, only the impairment in adenylyl cyclase activation progresses |
| Q35816081 | Decreased adrenergic neuronal uptake activity in experimental right heart failure. A chamber-specific contributor to beta-adrenoceptor downregulation. |
| Q47985713 | Decreased beta-adrenergic receptor density in rat myocardium during hemorrhagic shock |
| Q37239720 | Decreased beta-adrenergic responsiveness following hypertrophy occurs only in cardiomyocytes that also re-express beta-myosin heavy chain |
| Q34577351 | Decreased bioactivity of the guanine nucleotide-binding protein that stimulates adenylate cyclase in hearts from cardiomyopathic Syrian hamsters |
| Q89123147 | Decreased contractility and altered responses to inotropic agents in myocytes from tachypacing-induced heart failure canines |
| Q71959372 | Decreased inotropic but relatively preserved relaxation response to cyclic adenosine monophosphate-dependent agents in myopathic human myocardium |
| Q70939356 | Decreased inotropic response to beta-adrenergic stimulation and normal sarcoplasmic reticulum calcium stores in the spontaneously hypertensive rat heart |
| Q28305791 | Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure |
| Q35809366 | Decreased stimulatory guanosine triphosphate binding protein in dogs with pressure-overload left ventricular failure |
| Q71851313 | Deficient cellular cyclic AMP may cause both cardiac and skeletal muscle dysfunction in heart failure |
| Q44244540 | Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment |
| Q68477905 | Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats |
| Q59385092 | Desensitization of the pulmonary adenylyl cyclase system |
| Q36551968 | Detrimental effects of beta-adrenergic stimulation on beta-adrenoceptors and microtubules in the heart |
| Q35042408 | Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium |
| Q35690709 | Different subcellular populations of L-type Ca2+ channels exhibit unique regulation and functional roles in cardiomyocytes |
| Q35117586 | Differential cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy |
| Q73957821 | Differential nature of cross-talk among three G-coupled receptors regulating adenylyl cyclase in rat cardiomyocytes chronically exposed to receptor agonists |
| Q34239527 | Differential regulation of right and left ventricular beta-adrenergic receptors in newborn lambs with experimental cyanotic heart disease |
| Q37382594 | Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart |
| Q71959382 | Direct effects of chronic beta-adrenergic receptor blockade on left ventricular and myocyte function in a model of tachycardia-induced congestive heart failure |
| Q68244101 | Distinct down-regulation of cardiac beta 1- and beta 2-adrenoceptors in different human heart diseases |
| Q54117674 | Do human cardiac beta-2 adrenoceptors play a (patho)physiological role in regulation of heart rate and/or contractility? |
| Q43566119 | Dobutamine as bridge to angiotensin-converting enzyme inhibitor-nitrate therapy in endstage heart failure |
| Q43867413 | Dobutamine echocardiography in idiopathic dilated cardiomyopathy: clinical and prognostic implications. |
| Q41057089 | Dobutamine stress echocardiography for assessment of systolic function in dogs with experimentally induced mitral regurgitation. |
| Q53879157 | Dobutamine: positive inotropy by nonselective adrenoceptor agonism in isolated guinea pig and human myocardium. |
| Q68294938 | Dopexamine: a new catecholamine used in the treatment of low cardiac output after heart surgery |
| Q44079566 | Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). |
| Q71807524 | Dose-Dependent Dissociation of ACE-Inhibitor Effects on Blood Pressure, Cardiac Hypertrophy, and β-Adrenergic Signal Transduction |
| Q47655251 | Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium |
| Q53961836 | Dose-related hemodynamic and electrocardiographic effects of the calcium promoter BAY y 5959 in the presence or absence of congestive heart failure. |
| Q70458019 | Down-regulated beta-adrenoceptors in severely failing human ventricles: uniform regional distribution, but no increased internalization |
| Q35025991 | Down-regulation of aortic and cardiac AT1 receptor gene expression in transgenic (mRen-2) 27 rats |
| Q74123469 | Downstream defects in beta-adrenergic signaling and relation to myocyte contractility after cardioplegic arrest |
| Q38037989 | Drugs and receptors. An overview of the current state of knowledge |
| Q70962667 | EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium |
| Q42738826 | Early cardiac electrographic and molecular remodeling in a model of status epilepticus and acquired epilepsy. |
| Q44452106 | Echocardiographic study of left ventricular function in type 1 diabetes mellitus: hypersensitivity of beta-adrenergic stimulation |
| Q30279182 | Effect of Scar Compaction on the Therapeutic Efficacy of Anisotropic Reinforcement Following Myocardial Infarction in the Dog. |
| Q72164959 | Effect of captopril on myocardial beta-adrenoceptor density and Gi alpha-proteins in patients with mild to moderate heart failure due to dilated cardiomyopathy |
| Q57786070 | Effect of dobutamine on regional left ventricular function measured by tagged magnetic resonance imaging in normal subjects |
| Q71699836 | Effect of epinine on tension of human renal arteries |
| Q74143812 | Effect of long-term beta2-agonist dosing on human cardiac beta-adrenoceptor expression in vivo: comparison with changes in lung and mononuclear leukocyte beta-receptors |
| Q72267719 | Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators |
| Q37173639 | Effect of maternal nutrient restriction from early to midgestation on cardiac function and metabolism after adolescent-onset obesity. |
| Q36531828 | Effect of medical therapy on survival of patients with dilated cardiomyopathy |
| Q41839816 | Effects of autologous bone marrow stem cell transplantation on beta-adrenoceptor density and electrical activation pattern in a rabbit model of non-ischemic heart failure |
| Q34112955 | Effects of beta-blockers on neurohormonal activation in patients with congestive heart failure |
| Q42074948 | Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts |
| Q34153068 | Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation |
| Q28330767 | Effects of chronic pindolol treatment on human myocardial beta 1- and beta 2-adrenoceptor function |
| Q71312281 | Effects of continuous positive airway pressure on cardiac output and plasma norepinephrine in sedated pigs |
| Q43263421 | Effects of different beta adrenoceptor ligands in mice with permanent occlusion of the left anterior descending coronary artery |
| Q42979461 | Effects of enalapril on myocardial noradrenaline overflow during exercise in patients with chronic heart failure |
| Q74635749 | Effects of endotoxin on human myocardial contractility involvement of nitric oxide and peroxynitrite |
| Q72580731 | Effects of in vivo treatment with isoprenaline or prenalterol on beta-adrenoceptor mechanisms in the heart and soleus muscle of the cat |
| Q36042525 | Effects of increased preload on the force-frequency response and contractile kinetics in early stages of cardiac muscle hypertrophy |
| Q54116801 | Effects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failure. |
| Q73950824 | Effects of methylprednisolone on hemodynamics and beta-adrenergic receptor signaling in rabbits with acute left ventricular failure |
| Q43574450 | Effects of phorbol ester on contraction, intracellular pH and intracellular Ca2+ in isolated mammalian ventricular myocytes |
| Q30534707 | Effects of pressure overload, left ventricular hypertrophy on beta-adrenergic receptors, and responsiveness to catecholamines |
| Q54180136 | Effects of pulsed beta-stimulant therapy on beta-adrenoceptors and chronotropic responsiveness in chronic heart failure. |
| Q54319228 | Effects of short-term administration of dobutamine on left ventricular performance, exercise capacity, norepinephrine levels, and lymphocyte adrenergic receptor density in congestive heart failure. |
| Q35044907 | Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure |
| Q41870229 | Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure. |
| Q42005279 | Effects of three histaminergic compounds on function and oxygen consumption of isolated guinea-pig hearts |
| Q42625973 | Effects of treatment with a 5-HT4 receptor antagonist in heart failure |
| Q34397513 | Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure |
| Q54409186 | Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. |
| Q41647701 | Efficacy of beta blockers in idiopathic dilated cardiomyopathy and ischemic cardiomyopathy |
| Q34578568 | Electrical and structural remodeling of the failing ventricle |
| Q41892329 | Electrophysiological disturbances in heart failure |
| Q42111941 | Endothelial G protein-coupled receptor kinase 2 regulates vascular homeostasis through the control of free radical oxygen species |
| Q91809028 | Enhanced beta-1 adrenergic receptor responsiveness in coronary arterioles following intravenous stromal vascular fraction therapy in aged rats |
| Q45872754 | Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor |
| Q42394084 | Enhanced phosphorylation-independent arrestins and gene therapy |
| Q71043641 | Enhanced sensitivity of the failing human myocardium to cardiac glycosides and Na(+)-channel activators |
| Q33853399 | Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery |
| Q69841697 | Enhancement of the effectiveness of milrinone to increase force of contraction by stimulation of cardiac beta-adrenoceptors in the failing human heart |
| Q28330157 | Enoximone: true inotropic effects? Do they cause ischemia? Analysis of end-systolic pressure-volume relations using the conductance (volume) catheter technique |
| Q37992521 | Epinephrine in cardiac arrest: a critical review |
| Q68745917 | Epinephrine versus norepinephrine |
| Q89454332 | Etiology-dependent impairment of relaxation kinetics in right ventricular end-stage failing human myocardium |
| Q37399543 | Evaluating presynaptic and postsynaptic innervation in heart failure |
| Q71328286 | Evaluating the efficacy of new inotropic agents |
| Q43201901 | Evaluation of cardiac beta 1‐adrenergic sensitivity with dobutamine in healthy volunteers |
| Q50758578 | Evidence against a role of nitric oxide in the indirect negative inotropic-effect of M-cholinoceptor stimulation in human ventricular myocardium. |
| Q68085554 | Evidence against spare or uncoupled beta-adrenoceptors in the human heart |
| Q40713714 | Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure |
| Q77802837 | Evidence of phenotypic alteration as a cause of systolic dysfunction in the failing heart |
| Q77738058 | Evolving therapeutic concepts and imaging in ischemic cardiomyopathy |
| Q24650383 | Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice |
| Q71959367 | Expression of adenylyl cyclase and G-protein beta subunit in end-stage human heart failure |
| Q35821927 | Expression of dihydropyridine receptor (Ca2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure |
| Q35112394 | Extended-Release Metoprolol Succinate in Chronic Heart Failure |
| Q26739009 | Fatty old hearts: role of cardiac lipotoxicity in age-related cardiomyopathy |
| Q28325222 | Felodipine: A New Dihydropyridine Calcium-Channel Antagonist |
| Q71329908 | Fish oil and other nutritional adjuvants for treatment of congestive heart failure |
| Q36043165 | Flow Cytometric Quantification of Peripheral Blood Cell β-Adrenergic Receptor Density and Urinary Endothelial Cell-Derived Microparticles in Pulmonary Arterial Hypertension |
| Q41265608 | Force relaxation and thin filament protein phosphorylation during acute myocardial ischemia |
| Q46086271 | Force-frequency relations in the failing rabbit heart and responses to adrenergic stimulation |
| Q68146280 | Force-frequency relationship and inotropic stimulation in the nonfailing and failing human myocardium: implications for the medical treatment of heart failure |
| Q33938713 | Functional consequences of altering myocardial adrenergic receptor signaling |
| Q42512027 | Functional properties of the rat phosphatase 1alpha promoter |
| Q50132075 | Functions of PDE3 Isoforms in Cardiac Muscle |
| Q33810086 | G alpha(q)-mediated activation of GRK2 by mechanical stretch in cardiac myocytes: the role of protein kinase C. |
| Q37184794 | G protein betagamma subunits as targets for small molecule therapeutic development |
| Q35135090 | G protein coupled receptor kinases as therapeutic targets in cardiovascular disease |
| Q33604042 | G protein-coupled Receptor Kinase 2 as a Therapeutic Target for Heart Failure |
| Q37881660 | G protein-coupled receptor kinases in normal and failing myocardium |
| Q33639685 | G protein-coupled receptors in cardiac biology: old and new receptors |
| Q42528309 | G proteins, adenylyl cyclase and related phosphoproteins in the developing rat heart |
| Q35660111 | GRK2 and β-arrestins in cardiovascular disease: Something old, something new. |
| Q37783642 | GRK2 as a novel gene therapy target in heart failure. |
| Q35218715 | Gene interventions in the beta-adrenergic system for treating heart failure |
| Q36944623 | Gene therapy in heart failure |
| Q37310450 | Gene therapy to treat cardiovascular disease |
| Q36698991 | Gene transfer for congestive heart failure: update 2013. |
| Q95823497 | Genetic and phenotypic targeting of β-adrenergic signaling in heart failure |
| Q34016827 | Haemodynamic response to dopexamine hydrochloride in postinfarction heart failure: lack of tolerance after continuous infusion |
| Q38186583 | Heart failure-specific changes in protein kinase signalling. |
| Q34325932 | Heart rate variability in chronic heart failure |
| Q57422785 | Heart rhythms, ventricular arrhythmias,and death in chronic heart failure |
| Q39828490 | Heart transplantation |
| Q73476808 | Hemodynamic and clinical effects of oral levodopa in children with congestive heart failure |
| Q72695879 | Hemodynamic effects of the novel cardiotonic drug simendan: echocardiographic assessment in healthy volunteers |
| Q71959363 | Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy |
| Q54092891 | Hemodynamic responses during leg press exercise in patients with chronic congestive heart failure. |
| Q40179166 | Hemodynamics in hypertension and heart failure |
| Q71870050 | Heterotrimeric G proteins in heart disease |
| Q36822662 | Hibernating myocardium in post-ischaemic heart failure: pathophysiology, identification and revascularisation |
| Q47327873 | High-dose epinephrine improves outcome from pediatric cardiac arrest |
| Q49389901 | Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial). |
| Q24568237 | Histone deacetylase signaling in cardioprotection |
| Q47671855 | Human SERCA2a levels correlate inversely with age in senescent human myocardium |
| Q37427881 | Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state |
| Q71945620 | Hypertrophic cardiomyopathy: A desensitized cardiac \-adrenergic system in the presence of normal plasma catecholamine concentrations |
| Q39702719 | Hypocalcemia and hypophosphatemia in acutely ill patients. |
| Q37509834 | Hypoxia sensing through β-adrenergic receptors |
| Q37222188 | Imaging left ventricular remodeling: targeting the neurohumoral axis |
| Q74143829 | Imaging of cardiac neuronal and receptor function |
| Q36267057 | Imaging of metabolism and autonomic innervation of the heart by positron emission tomography. |
| Q42077100 | Immune modulation of cardiac cell function |
| Q44223785 | Impact of age on myocardial uptake of ¹²³I-mIBG in older adult subjects without coronary heart disease |
| Q39692006 | Impact of aging on cardiac sympathetic innervation measured by 123I-mIBG imaging in patients with systolic heart failure |
| Q41155058 | Impaired Inotropic Responses to Adrenergic Stimulation Following Aortic Constriction: Role of Oxidation Product of Catecholamines |
| Q60182009 | Impaired β-adrenergic responsiveness accentuates dysfunctional excitation-contraction coupling in an ovine model of tachypacing-induced heart failure |
| Q34118813 | Impairment of diastolic function by shortened filling period in severe left ventricular disease |
| Q33999920 | Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies |
| Q70463340 | Improved method for autoradiographic localization of beta-adrenoceptors using photoaffinity labelling |
| Q41321446 | Improved myocardial oxygen utilization following propranolol infusion in adolescents with postburn hypermetabolism |
| Q35540748 | Improvement of cardiac contractile function by peptide-based inhibition of NF-κB in the utrophin/dystrophin-deficient murine model of muscular dystrophy |
| Q78108722 | In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function |
| Q33936885 | In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction |
| Q36329813 | Incomplete reversal of β‐adrenoceptor desensitization in human and guinea‐pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors |
| Q34557266 | Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart |
| Q77535879 | Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure |
| Q34567917 | Increased fat and skeletal muscle beta-adrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrine in vivo in experimental human thyrotoxicosis |
| Q34119551 | Increased production of nitric oxide in coronary arteries during congestive heart failure |
| Q38677735 | Induction of cardiac dysfunction in developing and adult zebrafish by chronic isoproterenol stimulation |
| Q60908782 | Influence of Beta-1 Adrenergic Receptor Genotype on Cardiovascular Response to Exercise in Healthy Subjects |
| Q68778873 | Influence of cardiovascular diseases upon the results of the cardiovascular reflex tests in diabetic and nondiabetic subjects |
| Q35100887 | Inhibition of Na+/H+-exchanger with sabiporide attenuates the downregulation and uncoupling of the myocardial beta-adrenoceptor system in failing rabbit hearts. |
| Q37078266 | Inhibition of angiotensin II Gq signaling augments beta-adrenergic receptor mediated effects in a renal artery stenosis model of high blood pressure |
| Q43708435 | Inhibition of betaARK1 restores impaired biochemical beta-adrenergic receptor responsiveness but does not rescue CREB(A133) induced cardiomyopathy |
| Q39904074 | Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure |
| Q42487361 | Inhibition of spontaneous beta 2-adrenergic activation rescues beta 1-adrenergic contractile response in cardiomyocytes overexpressing beta 2-adrenoceptor |
| Q73646188 | Inotropes in the beta-blocker era |
| Q42253213 | Inotropic and electrophysiological effects of BDF 9148, a congener of DPI 201-106, in guinea-pig atria and papillary muscles |
| Q35756777 | Inotropic response to DPI 201-106 in the failing human heart |
| Q73597633 | Inotropic responses to isoproterenol in congestive heart failure subsequent to myocardial infarction in rats |
| Q40487973 | Inotropic support of the critically ill patient. A review of the agents |
| Q39562288 | Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. |
| Q64767181 | Interactions between the autonomic nervous system and tachycardias in man |
| Q41918298 | Interstitial remodeling in beta1-adrenergic receptor transgenic mice |
| Q38389875 | Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial |
| Q64381002 | Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)-adrenergic receptor in the heart : prospects for molecular ventricular assistance |
| Q35811171 | Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition |
| Q73591216 | Intranuclear mitochondria in human myocardial cells |
| Q36157352 | Intrathecal fentanyl blockade of afferent neural feedback from skeletal muscle during exercise in heart failure patients: Influence on circulatory power and pulmonary vascular capacitance |
| Q37221593 | Intravenous Followed by X-ray Fused with MRI-Guided Transendocardial Mesenchymal Stem Cell Injection Improves Contractility Reserve in a Swine Model of Myocardial Infarction. |
| Q41675685 | Iodine 123-labeled metaiodobenzylguanidine imaging in heart disease |
| Q38908301 | Is Heart Rate a Norepiphenomenon in Heart Failure? |
| Q35415155 | Is inotropic therapy for heart failure an unfulfilled promise? |
| Q34275369 | Is paradoxical pharmacology a strategy worth pursuing? |
| Q72403094 | Is the alpha adrenergic receptor density increased in intact thrombocytes in non-isometric trained athletes? |
| Q40599753 | Is there a role for positive inotropic agents in congestive heart failure: focus on mortality |
| Q73862565 | Ischemic versus idiopathic cardiomyopathy: differing neurohumoral profiles despite comparable peak oxygen uptake |
| Q34978520 | Isoform selectivity of adenylyl cyclase inhibitors: characterization of known and novel compounds |
| Q36594157 | Isolated neonatal rat papillary muscles: a new model to translate neonatal rat myocyte signaling into contractile mechanics |
| Q24320070 | Junctin and the histidine-rich Ca2+ binding protein: potential roles in heart failure and arrhythmogenesis |
| Q44293671 | Kidney function in heart failure |
| Q34212291 | Kinetics of cardiac muscle contraction and relaxation are linked and determined by properties of the cardiac sarcomere. |
| Q77111366 | L-type calcium current in human ventricular myocytes at a physiological temperature from children with tetralogy of Fallot |
| Q44582053 | Lack of inverse agonistic activity of nebivolol, its D- and L-enantiomers and of in vivo metabolized nebivolol in human myocardium |
| Q59684598 | Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure |
| Q43788597 | Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy |
| Q53698175 | Left ventricular remodelling in chronic primary mitral regurgitation: implications for medical therapy. |
| Q54668862 | Length dependence of force generation exhibit similarities between rat cardiac myocytes and skeletal muscle fibres. |
| Q45236710 | Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure |
| Q48747845 | Levosimendan improves diastolic and systolic function in failing human myocardium. |
| Q52066587 | Linear and non-linear 24 h heart rate variability in chronic heart failure. |
| Q51740622 | Long-Term Caloric Restriction Improves Cardiac Function, Remodeling, Adrenergic Responsiveness, and Sympathetic Innervation in a Model of Postischemic Heart Failure. |
| Q44136289 | Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy |
| Q42276633 | Long-term Treatment With Angiotensin I–Converting Enzyme Inhibitors Attenuates the Loss of Cardiac β-Adrenoceptor Responses in Rats With Chronic Heart Failure |
| Q38734731 | Long-term intravenous inotropes in low-output terminal heart failure? |
| Q34569359 | Loss of high affinity cardiac beta adrenergic receptors in dogs with heart failure |
| Q37209626 | Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice |
| Q36899686 | Low-level vagus nerve stimulation upregulates small conductance calcium-activated potassium channels in the stellate ganglion |
| Q34531254 | MIBG imaging |
| Q44389057 | MIBG imaging for selecting heart failure patients for defibrillator therapy: a first step |
| Q73902331 | MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing |
| Q69495372 | Management of arrhythmias in heart failure |
| Q34443742 | Managing heart failure with immunomodulatory agents |
| Q72540245 | Marked enhancement in myocardial function resulting from overexpression of a human beta-adrenergic receptor gene |
| Q41669348 | Mechanism of action of beta-blocking agents in heart failure |
| Q67708830 | Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations |
| Q39310132 | Mechanisms of SR calcium release in healthy and failing human hearts |
| Q41259301 | Mechanisms of beta-adrenergic receptor desensitization: from molecular biology to heart failure |
| Q40094154 | Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors |
| Q38303661 | Mechanisms of positive inotropic effects |
| Q33866666 | Mechanisms of regulation and function of G-protein-coupled receptor kinases |
| Q40444197 | Mechanisms, diagnosis, and treatment of diastolic heart failure |
| Q33558612 | Medical management of congestive heart failure. |
| Q77802846 | Medical therapy of chronic heart failure. Role of ACE inhibitors and beta-blockers |
| Q71126004 | Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic or ischemic dilated cardiomyopathy |
| Q42475549 | Method-related effects of adenovirus-mediated LacZ and SERCA1 gene transfer on contractile behavior of cultured failing human cardiomyocytes. |
| Q43656945 | Metoprolol attenuates postischemic depressed myocardial function in papillary muscles isolated from normal and postinfarction rat hearts |
| Q71514097 | Metoprolol in dilated cardiomyopathy: is it possible to identify factors predictive of improvement? The Heart Muscle Disease Study Group |
| Q33748197 | Mice lacking the Cβ subunit of PKA are resistant to angiotensin II-induced cardiac hypertrophy and dysfunction |
| Q34794475 | MicroRNA let-7 establishes expression of beta2-adrenergic receptors and dynamically down-regulates agonist-promoted down-regulation |
| Q24653709 | MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths |
| Q36634010 | Mild metabolic acidosis impairs the β-adrenergic response in isolated human failing myocardium. |
| Q54089909 | Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. |
| Q34357125 | Mitigation of beta 1- and/or beta 2-adrenoceptor function in human heart failure |
| Q34272692 | Mitral valve reconstruction in the patient with heart failure |
| Q73290155 | Mitral valve repair in heart failure |
| Q30433804 | Modeling cardiac β-adrenergic signaling with normalized-Hill differential equations: comparison with a biochemical model |
| Q30371695 | Modeling the effects of β1-adrenergic receptor blockers and polymorphisms on cardiac myocyte Ca2+ handling. |
| Q28255887 | Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes |
| Q51749399 | Moderate Continuous Aerobic Exercise Training Improves Cardiomyocyte Contractility in Β1 Adrenergic Receptor Knockout Mice. |
| Q34150128 | Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure |
| Q71867473 | Modulation of Left and Right Ventricular β-Adrenergic Receptors From Spontaneously Hypertensive Rats With Left Ventricular Hypertrophy and Failure |
| Q36848480 | Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5. |
| Q41609763 | Molecular and cellular prospects for repair, augmentation, and replacement of the failing heart |
| Q77730225 | Molecular and functional mechanisms of right ventricular adaptation in chronic pulmonary hypertension |
| Q34032476 | Molecular aspects and gene therapy prospects for diastolic failure |
| Q42345701 | Molecular imaging in heart failure patients |
| Q38241365 | Molecular imaging to predict ventricular arrhythmia in heart failure |
| Q36984198 | Molecule specific effects of PKA-mediated phosphorylation on rat isolated heart and cardiac myofibrillar function |
| Q42190835 | Myocardial Function With Reduced Expression of the Sodium-Calcium Exchanger |
| Q33750874 | Myocardial G protein-coupled receptor kinases: implications for heart failure therapy |
| Q36828757 | Myocardial beta adrenoceptors and left ventricular function in hypertrophic cardiomyopathy |
| Q33892916 | Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure |
| Q41188796 | Myocardial beta-adrenergic receptor signaling in vivo: insights from transgenic mice |
| Q71270504 | Myocardial beta-adrenoceptor density and plasma catecholamines in syndrome X |
| Q68238168 | Myocardial beta-adrenoceptor density and the distribution of beta 1- and beta 2-adrenoceptor subpopulations in children with congenital heart disease |
| Q53601215 | Myocardial beta-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[11C]CGP12388. |
| Q38282980 | Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy |
| Q71237109 | Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy: a biopsy study |
| Q41700817 | Myocardial contractile reserve on dobutamine echocardiography predicts late spontaneous improvement in cardiac function in patients with recent onset idiopathic dilated cardiomyopathy |
| Q44008848 | Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol. |
| Q71518858 | Myocardial defect detected by 123I-BMIPP scintigraphy and left ventricular dysfunction in patients with idiopathic dilated cardiomyopathy |
| Q68745118 | Myocardial energetics and efficiency in patients with idiopathic cardiomyopathy: response to dobutamine and amrinone |
| Q73769848 | Myocardial function in hearts with transgenic overexpression of the G protein-coupled receptor kinase 5 |
| Q44563021 | Myocardial gene expression of matched hibernating and control tissue from patients with ischemic left ventricular dysfunction |
| Q34119456 | Myocardial gene transfer |
| Q35872400 | Myocardial hypertrophy, cardiac beta-adrenoceptors and adenylate cyclase activity during sinoaortic denervation in dogs. |
| Q79759787 | Myocardial pre-synaptic sympathetic function correlates with glucose uptake in the failing human heart |
| Q55080592 | Myocardial remodeling and susceptibility to ventricular tachycardia in a model of chronic epilepsy. |
| Q33825289 | Myocyte contractile dysfunction with hypertrophy and failure: relevance to cardiac surgery |
| Q37357150 | Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrenergically mediated protein phosphorylation |
| Q36593277 | Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies |
| Q24561412 | Myosin heavy chain gene expression in human heart failure |
| Q72970854 | N-isopropyl-p-iodoamphetamine receptors in normal and cancerous tissue of the human lung |
| Q28345779 | Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium |
| Q37470858 | Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms |
| Q34173595 | Neural control of blood flow during exercise in human metabolic syndrome |
| Q39649942 | Neuroendocrine manifestations of congestive heart failure |
| Q38973209 | Neurohormonal activation in heart failure with reduced ejection fraction |
| Q38365094 | Neurohumoral activation in congestive heart failure: a double-edged sword? |
| Q58790122 | New Insights in Cardiac β-Adrenergic Signaling During Heart Failure and Aging |
| Q27011866 | New SPECT and PET radiopharmaceuticals for imaging cardiovascular disease |
| Q41724223 | New developments in cardiovascular adrenergic receptor pharmacology: molecular mechanisms and clinical relevance |
| Q34782396 | New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies |
| Q37822833 | New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma |
| Q36515530 | New signaling pathways associated with increased cardiac adenylyl cyclase 6 expression: implications for possible congestive heart failure therapy |
| Q34687109 | Newer positive inotropic agents in the treatment of chronic cardiac failure. Current status and future directions |
| Q85302130 | Non-classical regulation of β1- and β 2-adrenoceptor-mediated inotropic responses in rat heart ventricle by the G protein Gi |
| Q34327056 | Noncanonical EF-hand motif strategically delays Ca2+ buffering to enhance cardiac performance |
| Q35595409 | Noncoordinate regulation of cardiac Gs protein and beta-adrenergic receptors by a physiological stimulus, chronic dynamic exercise |
| Q67673943 | Noninvasive Exploration of Cardiac Arrhythmias |
| Q34544890 | Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology |
| Q54977622 | Novel paradigms governing β1-adrenergic receptor trafficking in primary adult rat cardiac myocytes. |
| Q41856322 | Novel strategies for the treatment of heart failure |
| Q36244456 | Outpatient Dobutamine Therapy: The Rhyme and the Riddle |
| Q35665407 | Outpatient management of congestive heart failure |
| Q37381474 | Overexpression of myocardial Gsalpha prevents full expression of catecholamine desensitization despite increased beta-adrenergic receptor kinase |
| Q77400619 | Overexpression of nerve growth factor in the heart alters ion channel activity and beta-adrenergic signalling in an adult transgenic mouse |
| Q37941174 | PDE3 inhibition in dilated cardiomyopathy |
| Q42155453 | PDE4 in the human heart - major player or little helper? |
| Q22254160 | PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts |
| Q27671474 | Paroxetine Is a Direct Inhibitor of G Protein-Coupled Receptor Kinase 2 and Increases Myocardial Contractility |
| Q36623426 | Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction |
| Q35146909 | Pathogenetic basis of myocardial dysfunction and amenability to reversal |
| Q71694107 | Pathophysiologic significance of left ventricular hypertrophy in dilated cardiomyopathy |
| Q40905686 | Pathophysiology and treatment of circulatory shock. |
| Q30315815 | Pathophysiology of Heart Failure |
| Q40780795 | Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). |
| Q35033114 | Perturbed atrial calcium handling in an ovine model of heart failure: potential roles for reductions in the L-type calcium current |
| Q36459142 | Pharmacogenetics of the human beta-adrenergic receptors |
| Q44617780 | Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure |
| Q40905723 | Pharmacologic cardiovascular support. |
| Q72666125 | Pharmacologic management of heart failure: neurohormonal agents |
| Q39765399 | Pharmacologic management of the critically ill patient in the perioperative period--emphasis on the sepsis syndrome. |
| Q40926069 | Pharmacology and inotropic potential of forskolin in the human heart |
| Q51554788 | Phosphodiesterase 2: anti-adrenergic friend or hypertrophic foe in heart disease? |
| Q37106060 | Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock |
| Q28327140 | Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure |
| Q38682363 | Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure |
| Q40347242 | Phospholamban-mediated stimulation of Ca2+ uptake in sarcoplasmic reticulum from normal and failing hearts |
| Q41062629 | Phosphotransfer reactions as a means of G protein activation |
| Q52090035 | Physical activity decreases the number of beta-adrenergic receptors on human lymphocytes. |
| Q71870128 | Physician use of beta-adrenergic blocking therapy: a changing perspective |
| Q28085424 | Physiological Implications of Myocardial Scar Structure |
| Q38136643 | Physiology and pharmacology of the cardiovascular adrenergic system |
| Q35045865 | Plasma membrane‐associated nucleoside diphosphate kinase (nm23) in the heart is regulated by β‐adrenergic signaling |
| Q71807495 | Positive and Negative Inotropic Effects of dl -Sotalol and d -Sotalol in Failing and Nonfailing Human Myocardium Under Physiological Experimental Conditions |
| Q46577023 | Positive inotropic effects of the calcium channel activator Bay K 8644 on guinea-pig and human isolated myocardium |
| Q45197917 | Positive inotropic stimulation in the normal and insufficient human myocardium |
| Q28293706 | Positive inotropic therapy: an update and new agents |
| Q77213473 | Potential risk of beta-blockade withdrawal in congestive heart failure due to abrupt autonomic changes |
| Q37362466 | Potentiation of beta-adrenergic signaling by adenoviral-mediated gene transfer in adult rabbit ventricular myocytes |
| Q80695335 | Pre- and post-synaptic sympathetic function in human hibernating myocardium |
| Q28345978 | Prediction of contractile reserve by cyclic variation of integrated backscatter of the myocardium in patients with chronic left ventricular dysfunction |
| Q35366928 | Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. |
| Q60922430 | Prenatal Stress: Molecular Mechanisms and Cardiovascular Disease |
| Q24656335 | Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction |
| Q48008599 | Preserved Frank-Starling mechanism in human end stage heart failure |
| Q35023632 | Preserved cardiac function despite marked impairment of cAMP generation |
| Q85179679 | Presynaptic stimulus-release and postsynaptic compensatory changes in mice lacking the N-type calcium channel α1B-subunit |
| Q40160776 | Primary and secondary cardioneuropathies and their functional significance |
| Q70728586 | Proceedings of a symposium: Calcium metabolism and calcium channel blockers for understanding and treating hypertension |
| Q69718847 | Proceedings of the British Pharmacological Society. Leeds, 12th-14th July 1989. Abstracts |
| Q36757784 | Prognostic Value of Lymphocyte G Protein-Coupled Receptor Kinase-2 Protein Levels in Patients With Heart Failure |
| Q36391033 | Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. |
| Q26830145 | Prospects for gene transfer for clinical heart failure |
| Q34505964 | Protein kinase A catalytic subunit isoform PRKACA; History, function and physiology |
| Q50792575 | Protein kinase C regulation of cardiac calcium channels expressed in Xenopus oocytes. |
| Q71343626 | Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts |
| Q72587901 | Pulmonary Oedema Associated with β2-Sympathomimetic Treatment of Premature Labour |
| Q74154356 | QT interval lengthening in cardiac disease relates more to left ventricular systolic dysfunction than to autonomic function |
| Q50929427 | Quantitation of myosin in muscle |
| Q64123698 | Quantitative temporal analysis of protein dynamics in cardiac remodeling |
| Q34390058 | RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications |
| Q34130282 | Rapid desensitization of neonatal rat liver beta-adrenergic receptors. A role for beta-adrenergic receptor kinase |
| Q38196174 | Reactive oxygen species and excitation-contraction coupling in the context of cardiac pathology |
| Q41452822 | Recent advances in knowledge about beta-adrenergic receptors: application to clinical cardiology |
| Q41522913 | Recent advances in nuclear cardiology in the study of coronary artery disease |
| Q37615740 | Recent developments in the treatment of congestive heart failure |
| Q37233904 | Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers |
| Q70118159 | Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man |
| Q36390543 | Receptor function in heart failure |
| Q81105970 | Receptor function reserve: a new parameter for disease detection |
| Q37369510 | Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice |
| Q35872448 | Reduced alpha 1- and beta 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure |
| Q33909731 | Reduced beta 1 receptor messenger RNA abundance in the failing human heart |
| Q35553783 | Reduced beta-adrenergic receptor activation decreases G-protein expression and beta-adrenergic receptor kinase activity in porcine heart |
| Q33641335 | Reduced force production during low blood flow to the heart correlates with altered troponin I phosphorylation |
| Q73368325 | Reduced length-dependent cross-bridge recruitment in skinned fiber preparations of human failing myocardium |
| Q43876768 | Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity |
| Q46954786 | Reduced sarcoplasmic reticulum Ca(2+) load mediates impaired contractile reserve in right ventricular pressure overload |
| Q46600650 | Reduced troponin I phosphorylation and increased Ca(2+)-dependent ATP-consumption in triton X-skinned fiber preparations from Galphaq overexpressor mice |
| Q70856648 | Reduction in lymphocyte beta-adrenergic receptor density in infants and children with heart failure secondary to congenital heart disease |
| Q41084763 | Regional distribution of ?1- and ?2-adrenoceptors in the failing and nonfailing human heart |
| Q34070572 | Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family |
| Q33782643 | Regulation of cardiac contractility by Rab4-modulated beta2-adrenergic receptor recycling |
| Q38354732 | Regulation of cardiac β1-adrenergic receptor transcription during the developmental transition |
| Q36816705 | Regulation of cellular oxidative stress and apoptosis by G protein-coupled receptor kinase-2; The role of NADPH oxidase 4 |
| Q33538026 | Regulation of fibre contraction in a rat model of myocardial ischemia |
| Q36506527 | Regulation of mitochondrial oxidative stress by β-arrestins in cultured human cardiac fibroblasts |
| Q43703673 | Regulation of myocardial betaARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing alpha1B-adrenergic receptors |
| Q68242266 | Relation between myocardial beta-adrenergic receptor and left ventricular function in patients with left ventricular volume overload due to chronic mitral regurgitation with or without aortic regurgitation |
| Q44439743 | Relation of cardiac sympathetic innervation to proinflammatory cytokine levels in patients with heart failure secondary to idiopathic dilated cardiomyopathy |
| Q71972392 | Relation of iodine-123 metaiodobenzylguanidine myocardial scintigraphy to endomyocardial biopsy findings in patients with dilated cardiomyopathy |
| Q45005481 | Relations between beta-adrenoceptor occupancy and increases of contractile force and adenylate cyclase activity induced by catecholamines in human ventricular myocardium. Acute desensitization and comparison with feline ventricle |
| Q67900217 | Relationship between adenylate cyclase activity and regional myocardial energetics in experimental left ventricular hypertrophy |
| Q35887484 | Relationship between beta-adrenoceptors and calcium channels in human ventricular myocardium |
| Q50055043 | Relationship of left ventricular global longitudinal strain with cardiac autonomic denervation as assessed by 123I-mIBG scintigraphy in patients with heart failure with reduced ejection fraction submitted to cardiac resynchronization therapy : Asses |
| Q70061445 | Relative attenuation of sympathetic drive during exercise in patients with congestive heart failure |
| Q28295123 | Removal of the N-terminal extension of cardiac troponin I as a functional compensation for impaired myocardial beta-adrenergic signaling |
| Q67506285 | Renal beta-adrenoceptors in thyroxine-treated rats |
| Q40976394 | Renal denervation improves cardiac function in rats with chronic heart failure: Effects on expression of β-adrenoceptors |
| Q57778967 | Renal effects of low-dose dopamine in patients with sepsis syndrome or septic shock treated with catecholamines |
| Q72034159 | Response of Failing Canine and Human Heart Cells to β 2 -Adrenergic Stimulation |
| Q36637020 | Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer |
| Q33876021 | Reversal of impaired myocardial beta-adrenergic receptor signaling by continuous-flow left ventricular assist device support |
| Q37964927 | Reverse remodeling in heart failure--mechanisms and therapeutic opportunities |
| Q26746907 | Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies |
| Q46276226 | Role of Beta-adrenergic Receptors and Sirtuin Signaling in the Heart During Aging, Heart Failure, and Adaptation to Stress |
| Q41715870 | Role of cytokines in heart failure |
| Q35818139 | Role of intact cardiac nerves and reflex mechanisms in desensitization to catecholamines in conscious dogs |
| Q35106474 | Role of nonglycosidic inotropic agents: indications, ethics, and limitations |
| Q38820202 | Role of protein phosphatase inhibitor-1 in cardiac beta adrenergic pathway |
| Q70880316 | Role of spectral measures of heart rate variability as markers of disease progression in patients with chronic congestive heart failure not treated with angiotensin-converting enzyme inhibitors |
| Q35762284 | Role of substrate and triggers in the genesis of cardiac alternans, from the myocyte to the whole heart: implications for therapy |
| Q54378532 | Role of the beta 2 adrenoceptor in mediating positive inotropic activity in the failing heart and its relation to the hemodynamic actions of dopexamine hydrochloride. |
| Q33912937 | Ryanodine receptor channelopathies |
| Q37248371 | Ryanodine receptor-mediated arrhythmias and sudden cardiac death. |
| Q28240412 | S100A1 in human heart failure: lack of recovery following left ventricular assist device support |
| Q92904259 | Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome |
| Q44279875 | Sarcolemmal beta-adrenoceptors determined in rat ventricular heart biopsies with (-)-[3H]CGP-12177. |
| Q37200169 | Sarcomere length dependence of power output is increased after PKA treatment in rat cardiac myocytes |
| Q71665345 | Sarcoplasmic reticulum Ca2+ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy |
| Q48008693 | Sarcoplasmic reticulum in heart failure: central player or bystander? |
| Q33919826 | Selection, design and evaluation of new radioligands for PET studies of cardiac adrenoceptors |
| Q43688881 | Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging |
| Q35755691 | Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment |
| Q39148010 | Selective updates on mechanisms of action of positive inotropic agents |
| Q51183535 | Selective upregulation of beta1-adrenergic receptors and dephosphorylation of troponin I in end-stage heart failure patients supported by ventricular assist devices. |
| Q38138743 | Sepsis and the trauma patient. |
| Q60922459 | Sex-Related Effects of Prenatal Stress on Region-Specific Expression of Monoamine Oxidase A and β Adrenergic Receptors in Rat Hearts |
| Q34407902 | Short-term erythropoietin treatment does not substantially modulate monocyte transcriptomes of patients with combined heart and renal failure |
| Q28318119 | Significance of adaptation mechanisms in adriamycin induced congestive heart failure |
| Q41974755 | Simultaneous adrenal and cardiac g-protein-coupled receptor-gβγ inhibition halts heart failure progression |
| Q34077136 | Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure |
| Q36416038 | Some aspects of heart beta adrenoceptor function |
| Q33951980 | Soybean oil increases SERCA2a expression and left ventricular contractility in rats without change in arterial blood pressure |
| Q37868990 | Specific PI3K isoform modulation in heart failure: lessons from transgenic mice |
| Q72966236 | Spectral analysis of heart rate variability in the sepsis syndrome |
| Q54413506 | Static exercise with congestive heart failure and the response to vasodilating drugs. |
| Q35517542 | Stem and progenitor cell therapy for pulmonary arterial hypertension: effects on the right ventricle (2013 Grover Conference Series). |
| Q53867970 | Structure-Activity Relationships of Histamine H2-Agonists, a New Class of Positive Inotropic Drugs |
| Q41340211 | Sugemule-3 Protects against Isoprenaline-induced Cardiotoxicity In vitro |
| Q72591001 | Sulfinpyrazone increases the number of β-adrenoceptors on intact human lymphocytes |
| Q54395813 | Sustained hemodynamic improvement during long-term therapy with levodopa in heart failure: role of plasma catecholamines. |
| Q36085348 | Sustaining cardiac claudin-5 levels prevents functional hallmarks of cardiomyopathy in a muscular dystrophy mouse model. |
| Q35561947 | Switching Between Beta Blockers in Heart Failure Patients: Rationale and Practical Considerations |
| Q34097170 | Symbolic analysis detects alterations of cardiac autonomic modulation in congestive heart failure rats |
| Q89247755 | Sympathetic drive stimulating diastolic dysfunction? |
| Q72736313 | Sympathetic nervous system activation in postextrasystolic potentiation: role of catecholamine release in enhancement of ventricular function |
| Q35171874 | Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances. |
| Q70046494 | Systemic and regional vascular effects of atrial natriuretic peptide in a rat model of chronic heart failure |
| Q40605722 | Systemic inflammatory response syndrome: septic shock |
| Q36302132 | Systems biology and biomechanical model of heart failure |
| Q34150582 | Tachybradycardia in the isolated canine right atrium induced by chronic sympathetic stimulation and pacemaker current inhibition. |
| Q24322049 | Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts |
| Q36522556 | Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure |
| Q34460199 | Targeting G protein-coupled receptor kinases (GRKs) in Heart Failure |
| Q38153376 | Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy |
| Q35763705 | Targeting cardiomyocyte Ca2+ homeostasis in heart failure |
| Q38974127 | Targeting β3-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade. |
| Q40091746 | The Beta-Adrenergic Receptor in Heart Failure |
| Q36422577 | The Frank-Starling mechanism involves deceleration of cross-bridge kinetics and is preserved in failing human right ventricular myocardium |
| Q42817034 | The Gordon Wilson Lecture: neurohormonal signaling pathways that link cardiac growth and death. |
| Q37385715 | The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure |
| Q34505314 | The Ryanodine Receptor in Cardiac Physiology and Disease |
| Q39654047 | The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients |
| Q35888279 | The anti-adrenergic effect of adenosine and its blockade by pertussis toxin: a comparative study in myocytes isolated from guinea-pig, rat and failing human hearts |
| Q34495307 | The cardiorenal syndrome: a review |
| Q37074843 | The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure |
| Q37219835 | The choice of inotropes following cardiopulmonary bypass Pro: Amrinone is a first-choice inotrope following cardiopulmonary bypass |
| Q47687870 | The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform |
| Q36288169 | The cytoskeleton and related proteins in the human failing heart |
| Q90411083 | The deubiquitinase ubiquitin-specific protease 20 is a positive modulator of myocardial β1-adrenergic receptor expression and signaling |
| Q34443749 | The dilemma of late-stage heart failure. Rationale for chronic parenteral inotropic support |
| Q34402982 | The effect of orthotopic transplantation on total, beta 1‐ and beta 2‐ adrenoceptors in the human heart |
| Q73862796 | The effect of salbutamol on skeletal muscle in chronic heart failure |
| Q38185200 | The effectiveness of inotropic agents in isolated cardiac preparations from the human heart |
| Q43960922 | The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure |
| Q30250314 | The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development |
| Q39469516 | The functional importance of beta 1 and beta 2 adrenoceptors in the human heart |
| Q35826772 | The functional significance of genetic variation within the beta-adrenoceptor |
| Q35754928 | The influence of atherosclerosis on the mechanical responses of human isolated coronary arteries to substance P, isoprenaline and noradrenaline |
| Q93662281 | The inotropic effects of dopamine and its precursor levodopa on isolated human ventricular myocardium |
| Q38365789 | The management of heart failure and the scope for new therapies: what role for xamoterol? |
| Q42858896 | The new HNO donor, 1-nitrosocyclohexyl acetate, increases contractile force in normal and β-adrenergically desensitized ventricular myocytes |
| Q46711826 | The positive inotropic response to milrinone in isolated human and guinea pig myocardium |
| Q37555074 | The role of CaMKII regulation of phospholamban activity in heart disease |
| Q39511387 | The role of exercise testing in chronic heart failure |
| Q33824143 | The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. |
| Q36819632 | The role of the adrenergic system in the heart: Regulation of contractility by cardiac adrenoceptors |
| Q69617275 | The search of an ideal oral positive inotropic agent |
| Q40650773 | The temporal hormesis of drug therapies |
| Q39493510 | The treatment of heart failure--what next? |
| Q44387849 | The use of amrinone and norepinephrine for inotropic support during emergence from cardiopulmonary bypass |
| Q38215931 | The use of angiotensin-converting enzyme inhibitors in congestive heart failure |
| Q38281750 | The war against heart failure: the Lancet lecture |
| Q36551979 | Therapy of idiopathic dilated cardiomyopathy with chronic β-adrenergic blockade |
| Q36014089 | Thr164Ile polymorphism of beta2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy |
| Q38248810 | Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure |
| Q42083736 | Time course and extent of alpha 1-adrenoceptor density changes in rat heart after beta-adrenoceptor blockade |
| Q46413734 | Time to re-think the use of dobutamine in sepsis |
| Q36003934 | Tissue response selectivity of calcium antagonists is not due to heterogeneity of [3H]-nitrendipine binding sites |
| Q40921182 | Tracer norepinephrine kinetics in coronary circulation of patients with heart failure secondary to chronic pressure and volume overload |
| Q34099660 | Transcriptional regulation by cAMP in the heart |
| Q40489196 | Treating relentlessly progressive congestive heart failure: what next? |
| Q51790187 | Treatment of low cardiac output after aortocoronary artery bypass surgery using a combination of norepinephrine and amrinone. |
| Q36970435 | Treatment of mild congestive heart failure. The potential for new drugs to reduce the risks |
| Q45081695 | Twenty-four-hour spectral analysis of heart rate variability in congestive heart failure secondary to coronary artery disease |
| Q34281889 | Type 1 phosphatase, a negative regulator of cardiac function |
| Q71807622 | Unchanged Protein Levels of SERCA II and Phospholamban but Reduced Ca 2+ Uptake and Ca 2+ -ATPase Activity of Cardiac Sarcoplasmic Reticulum From Dilated Cardiomyopathy Patients Compared With Patients With Nonfailing Hearts |
| Q44314798 | Upregulation of beta 1-adrenergic receptors in ovariectomized rat hearts |
| Q42490123 | Upregulation of the alpha1-adrenoceptor-induced phosphoinositide and inotropic response in hypothyroid rat heart. |
| Q40475658 | Use of beta-adrenoceptor blockers in patients with congestive heart failure |
| Q40094984 | Use of catecholamines in pediatrics |
| Q72933726 | What Is Wrong with the Failing Heart? |
| Q74315537 | What are we actually measuring by Doppler tissue imaging? |
| Q77296406 | Why does the myocardium fail? Insights from basic science |
| Q69375741 | Xamoterol and the failing heart |
| Q39472615 | Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. |
| Q70171113 | [Beta-adrenergic receptors and plasma catecholamine behavior in trained and untrained athletes] |
| Q54109231 | [Early hemodynamic effects of olprinone hydrochloride after coronary artery bypass grafting] |
| Q79242495 | [On the function of beta3-adrenoceptors in the human heart: signal transduction, inotropic effect and therapeutic prospects] |
| Q54420542 | [Regional blood flow in congestive cardiac failure and inhibition of angiotensin converting enzyme]. |
| Q43670404 | beta(1)-Adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes |
| Q35768797 | beta-Adrenergic modulation of the inwardly rectifying potassium channel in isolated human ventricular myocytes. Alteration in channel response to beta-adrenergic stimulation in failing human hearts |
| Q34057925 | beta-adrenergic mechanisms in cardiac diseases: a perspective |
| Q37771890 | betaARKct: a therapeutic approach for improved adrenergic signaling and function in heart disease |
| Q37235097 | β-Adrenergic receptor antagonism in mice: a model for pediatric heart disease. |
| Q33828730 | β-Adrenergic receptor subtype signaling in heart: from bench to bedside |
| Q98291427 | β-Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry |
| Q37453620 | β-adrenergic receptor responsiveness in aging heart and clinical implications |
| Q51831879 | β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling. |
| Q38266154 | β1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy |
| Q44591642 | β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure |
| Q34634348 | β₂ AR agonists in treatment of chronic heart failure: long path to translation |